Feedback
Settings

Settings

Goto Application

1. WO2022111616 - ANTI-CLDN18.2 ANTIBODY, DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Submit observation
PermaLink
Publication Number WO/2022/111616
Publication Date 02.06.2022
International Application No. PCT/CN2021/133376
International Filing Date 26.11.2021
IPC
A61K 47/68 2017.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/4745 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4738ortho- or peri-condensed with heterocyclic ring systems
4745condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/537 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
537spiro-condensed or forming part of bridged ring systems
A61K 38/07 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
07Tetrapeptides
A61K 45/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A61K 45/06 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
CPC
A61K 31/4745
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4738ortho- or peri-condensed with heterocyclic ring systems
4745condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
A61K 31/537
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
537spiro-condensed or forming part of bridged ring systems
A61K 38/07
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
07Tetrapeptides
A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Applicants
  • 石药集团巨石生物制药有限公司 CSPC MEGALITH BIOPHARMACEUTICAL CO., LTD. [CN]/[CN]
Inventors
  • 惠希武 HUI, Xiwu
  • 孙召朋 SUN, Zhaopeng
  • 曹卫荣 CAO, Weirong
  • 姚兵 YAO, Bing
  • 刘伯宁 LIU, Boning
  • 胡喜新 HU, Xixin
  • 袁灿 YUAN, Can
  • 李文宾 LI, Wenbin
  • 王艳翠 WANG, Yancui
Agents
  • 北京英赛嘉华知识产权代理有限责任公司 INSIGHT INTELLECTUAL PROPERTY LIMITED
Priority Data
202011385844.430.11.2020CN
Publication Language Chinese (zh)
Filing Language Chinese (ZH)
Designated States
Title
(EN) ANTI-CLDN18.2 ANTIBODY, DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF
(FR) ANTICORPS ANTI-CLDN18.2, CONJUGUÉ MÉDICAMENTEUX, PROCÉDÉ DE PRÉPARATION S'Y RAPPORTANT ET UTILISATION ASSOCIÉE
(ZH) 抗CLDN18.2抗体、药物偶联物及其制备方法和用途
front page image
Abstract
(EN) The present application provides an anti-CLDN18.2 antibody and an antibody-drug conjugate prepared from the antibody. The antibody or the antibody-drug conjugate can effectively treat CLDN18.2 positive tumors, comprising but not limited to cancers represented by gastric cancer and pancreatic cancer.
(FR) La présente demande concerne un anticorps anti-CLDN18.2 et un conjugué anticorps-médicament préparé à partir de l'anticorps. L'anticorps ou le conjugué anticorps-médicament peut traiter efficacement des tumeurs positives à CLDN18.2, comprenant, sans y être limitées, des cancers représentés par le cancer gastrique et le cancer du pancréas.
(ZH) 本申请提供抗CLDN18.2抗体及从所述抗体制备的抗体-药物缀合物，该抗体或抗体-药物缀合物能够有效治疗CLDN18.2阳性肿瘤，包括但不限于以胃癌和胰腺癌为代表的癌症。
Latest bibliographic data on file with the International Bureau
# -